Company Quick10K Filing
AbbVie
10-K 2019-12-31 Filed 2020-02-21
10-Q 2019-09-30 Filed 2019-11-06
10-Q 2019-06-30 Filed 2019-08-05
10-Q 2019-03-31 Filed 2019-05-03
10-K 2018-12-31 Filed 2019-02-27
10-Q 2018-09-30 Filed 2018-11-07
10-Q 2018-06-30 Filed 2018-08-07
10-Q 2018-03-31 Filed 2018-05-04
10-K 2017-12-31 Filed 2018-02-16
10-Q 2017-09-30 Filed 2017-11-07
10-Q 2017-06-30 Filed 2017-08-07
10-Q 2017-03-31 Filed 2017-05-05
10-K 2016-12-31 Filed 2017-02-17
10-Q 2016-09-30 Filed 2016-11-07
10-Q 2016-06-30 Filed 2016-08-05
10-Q 2016-03-31 Filed 2016-05-06
10-K 2015-12-31 Filed 2016-02-19
10-Q 2015-09-30 Filed 2015-11-06
10-Q 2015-06-30 Filed 2015-08-07
10-Q 2015-03-31 Filed 2015-05-08
10-K 2014-12-31 Filed 2015-02-20
10-Q 2014-09-30 Filed 2014-11-07
10-Q 2014-06-30 Filed 2014-08-07
10-Q 2014-03-31 Filed 2014-05-09
10-K 2013-12-31 Filed 2014-02-21
10-Q 2013-09-30 Filed 2013-11-12
10-Q 2013-03-31 Filed 2013-05-08
10-K 2012-12-31 Filed 2013-03-15
8-K 2020-03-23 Other Events, Exhibits
8-K 2020-03-09 Other Events, Exhibits
8-K 2020-02-24 Other Events, Exhibits
8-K 2020-02-11 Leave Agreement
8-K 2020-02-07 Earnings, Exhibits
8-K 2020-01-27 Other Events, Exhibits
8-K 2019-12-20 Other Events, Exhibits
8-K 2019-11-21 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-11-18 Other Events, Exhibits
8-K 2019-11-12 Enter Agreement, Exhibits
8-K 2019-11-07 Other Events, Exhibits
8-K 2019-11-07 Other Events, Exhibits
8-K 2019-11-06 Regulation FD, Other Events, Exhibits
8-K 2019-11-01 Earnings, Exhibits
8-K 2019-10-25 Other Events, Exhibits
8-K 2019-10-17
8-K 2019-09-26 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-09-17 Enter Agreement, Exhibits
8-K 2019-09-16 Regulation FD, Exhibits
8-K 2019-09-16 Other Events, Exhibits
8-K 2019-08-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-07-26 Earnings, Exhibits
8-K 2019-07-12 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-06-25 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-05-03 Shareholder Vote
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-01-25 Earnings, Exhibits
8-K 2019-01-04 Impairments
8-K 2019-01-04
8-K 2018-12-13 Officers, Exhibits
8-K 2018-11-02 Earnings, Exhibits
8-K 2018-10-16 Officers
8-K 2018-09-13 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2018-08-31 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2018-07-27 Earnings, Exhibits
8-K 2018-05-17 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-05-04 Shareholder Vote
8-K 2018-05-01 Suspend Trading, Exhibits
8-K 2018-04-26 Earnings, Other Events, Exhibits
8-K 2018-01-26 Earnings, Exhibits

AbbVie Financials

ABBV Metrics, Comps, Filings

Quarterly | Annual

Business

AbbVie(1) is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.

AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

AbbVie operates in one business segment-pharmaceutical products. See Note 15 to the Consolidated Financial Statements and the sales information related to HUMIRA, IMBRUVICA and MAVYRET included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Quarterly)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Abbott (ABT) 149,317 57% 26.2 5% 68,539 36,722 31,355 17,879 3,292 6,255 164,119
Eli Lilly (LLY) 105,897 78% 12.7 21% 37,893 34,431 22,644 17,612 7,948 9,419 119,560
AbbVie (ABBV) 109,786 77% 21.1 5% 59,441 67,667 32,867 25,412 3,255 6,259 132,264
Beigene (BGNE) 100,124 74% -123.1 -44% 1,881 587 430 318 -827 -807 99,328
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152

Balance Sheet ($MM)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash6,9798,7438,9759,5958,1409,0867,7198,3487,9067,4009,2238,3997,5566,3276,2185,1004,7406,0888,4469,3039,0073,5478,0157,2894,8975,17210,648
Accounts Receivable4,7535,0484,9994,6774,8594,8915,8415,7935,7805,3845,6805,4825,529
Inventory1,0371,0851,1721,1501,1041,0481,0081,1241,0221,6231,8411,7191,7891,7561,6301,4441,4271,5821,7851,6051,7381,5801,7861,6051,7021,8951,929
PP&E6,5456,6466,7906,9097,0167,1477,0557,1056,9887,1727,2817,3347,4897,6017,7107,5267,5967,7867,8948,0718,2318,2148,4498,3968,3708,4438,492
Assets27,16927,91028,25229,19828,65729,04528,45427,54726,69953,85554,83253,05053,72067,21166,62666,09965,66466,99468,84070,78669,34261,64166,16459,35256,76957,14259,441
Accounts Payable9338811,5971,4071,4741,546
Long-Term Debt14,60114,32614,37514,29214,38614,47014,46910,56510,68327,11631,35929,24029,49037,32837,28436,44036,52633,81733,97430,95330,90630,57936,48735,00235,06631,61933,126
Liabilities24,21224,35224,67524,70623,96023,82723,80925,80525,32248,35149,96949,10549,07761,57160,15761,46360,66660,98562,15365,68965,78965,01669,08567,79864,59565,70867,667
Stockholders' Equity2,9573,5583,5774,4924,6975,2184,6451,7421,3775,5044,8633,9454,6435,6406,4694,6364,9986,0096,6875,0973,553-3,375-2,921-8,446-7,826-8,566-8,226
Income Statement ($MM)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue4,3294,6924,6585,1114,5634,9265,0195,4525,0405,4755,9446,4005,9586,4526,4326,7966,5386,9446,9957,7397,9348,2788,2368,3057,8288,2558,479
Cost of Revenue1,2821,1191,4751,5552,2801,8352,0221,6941,8191,920
Gross Profit3,8294,3334,9255,2415,4596,4016,2836,1346,4366,559
R&D6347097147987728348128798119811,4181,0759461,1241,1061,1901,1351,2231,2221,4021,2441,3221,2681,2891,2912,285
SG&A1,2371,4061,2611,4481,3401,5271,5953,3411,4731,7031,4741,7371,3551,4661,3811,6531,3681,5041,4521,9511,7911,7601,9191,6801,6541,657
Tax271300322311306335181-2273743124084074224864166073754384641,1411429148866117
Net Income1,5981,3911,7111,9151,631522,7831,9832,747-1,8262,4567411,884
Cash Flow ($MM)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating1,1872,0371,7981,2456241,7171,786-5781,5851,8322,1551,9632,1281,9182,1022,0033,2712,6452,8664,5243,0172,4774,555
Cash Investing1,487233-964123-797-359-2,2842,514-873-12,511745-297-1,458-4,298-684318-109-447687-963-27-1401,378
Cash Financing-1,582-500-613-747-1,277-415-719-882-93010,169-1,056-2,431-1,2191,164-1,794-980-810-2,509-8,978916-5,383-2,070-441